Genfit (GNFT)

• Market cap: $181M
• 1 day: 1.40%
• 5 days: -1.89%
• 1 month: -10.59%
• 3 months: -4.97%
• 6 months: -9.02%
• Year to date: -5.22%
• 1 year: 2.83%
• 5 years: -70.73%
• 10 years: -83.63%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Employees: 167

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

62% more capital invested

Capital invested by funds: $465K [Q3] → $755K (+$290K) [Q4]

50% more funds holding

Funds holding: 4 [Q3] → 6 (+2) [Q4]

0.25% more ownership

Funds ownership: 0.16% [Q3] → 0.41% (+0.25%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $13 258% upside
• Avg. target: $13 258% upside
• High target: $13 258% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 41% 1-year accuracy 66 / 160 met price target

258% upside $13

Buy Reiterated

7 Feb 2025